{
  "input": {
    "mode": "execute_actions",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "items": [
      {
        "hypothesis_id": "H1",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "Acitretin Potential Risks",
            "expectation": "若存在不良反应，则在后续评估中降低其支持力度",
            "assignee": "Skeptic"
          }
        ]
      }
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_bimekizumab",
          "type": "Drug",
          "label": "Bimekizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ixekizumab",
          "type": "Drug",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tazarotene",
          "type": "Drug",
          "label": "Tazarotene",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "d_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised pustular psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_immune_response",
          "type": "Target",
          "label": "Immune Response",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_inflammatory_response",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_symptomatic_relief",
          "type": "Phenotype",
          "label": "Symptomatic Relief",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_skin_remission",
          "type": "Phenotype",
          "label": "Skin Remission",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_acitretin",
          "type": "Target",
          "label": "Acitretin Off-Target",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_acitretin",
          "type": "Pathway",
          "label": "Acitretin Risk Pathway",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_acitretin",
          "type": "Phenotype",
          "label": "Adverse Effects of Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_acitretin",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "常用治疗在免疫调节上有效"
        },
        {
          "source": "drug_adalimumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "靶向 TNF-α 的治疗策略"
        },
        {
          "source": "drug_apremilast",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "抑制炎症通路的机制"
        },
        {
          "source": "drug_bimekizumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "IL-17靶向作用"
        },
        {
          "source": "drug_brodalumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "IL-17A拮抗剂"
        },
        {
          "source": "drug_cyclosporine",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "免疫抑制机制支持"
        },
        {
          "source": "drug_etanercept",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "抑制炎症反应"
        },
        {
          "source": "drug_ixekizumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "IL-17E 的抵抗并促进重建"
        },
        {
          "source": "drug_methotrexate",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "作为传统治疗药物的有效性"
        },
        {
          "source": "drug_secukinumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "针对 IL-17A 的特异性干预"
        },
        {
          "source": "drug_tazarotene",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "调控分化的机制"
        },
        {
          "source": "drug_ustekinumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "靶向 IL-12/23 的选择性"
        },
        {
          "source": "target_immune_response",
          "target": "pathway_inflammatory_response",
          "relation": "involved_in",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "支持的通路连接"
        },
        {
          "source": "pathway_inflammatory_response",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "causes",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "与通路在病理过程中的一致性"
        },
        {
          "source": "drug_acitretin",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "已知的临床表现改善"
        },
        {
          "source": "drug_adalimumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "有效性证据强"
        },
        {
          "source": "drug_apremilast",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "机制的有效性总结"
        },
        {
          "source": "drug_bimekizumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "靶向的有效性"
        },
        {
          "source": "drug_brodalumab",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "支持的临床证据"
        },
        {
          "source": "drug_cyclosporine",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "提高患者群体的好转率"
        },
        {
          "source": "drug_etanercept",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "发挥快速生效"
        },
        {
          "source": "drug_ixekizumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "针对于根据临床效果获得改善"
        },
        {
          "source": "drug_methotrexate",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "已知的改善作用"
        },
        {
          "source": "drug_secukinumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "可期待的病理改善"
        },
        {
          "source": "drug_tazarotene",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "局部疗法已知效果"
        },
        {
          "source": "drug_ustekinumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "支持慢性病例治疗的有效性"
        },
        {
          "source": "drug_acitretin",
          "target": "n_ot_acitretin",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在的旁路作用导致不良反应"
        },
        {
          "source": "n_ot_acitretin",
          "target": "n_rp_acitretin",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能通过非靶向途径导致风险"
        },
        {
          "source": "n_rp_acitretin",
          "target": "n_adv_acitretin",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "导致不良表型"
        },
        {
          "source": "n_adv_acitretin",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若存在此风险，则抵消潜在疗效"
        }
      ],
      "round_index": 4
    },
    "constraints": {
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "hypothesis_id": "H1",
    "executed_actions": [
      {
        "action_ref": 0,
        "status": "done",
        "graph_updates": {
          "conflict_hotspots": [
            {
              "topic": "Acitretin Potential Risks",
              "pro_nodes": [
                "drug_acitretin",
                "phenotype_symptomatic_relief"
              ],
              "con_nodes": [
                "n_rp_acitretin",
                "n_adv_acitretin"
              ],
              "note": "潜在不良反应与疗效之间的矛盾"
            }
          ]
        },
        "notes": "已完成安全性压力测试：已将不良风险通过高权重边连到假设"
      }
    ],
    "unexecuted_actions": [],
    "residual_conflicts": [
      "不良反应的具体机制同仍需进一步阐明",
      "存在对比其他药物的疗效尚不清晰"
    ]
  }
}